Tag: Artificial Intelligence

The use of Artificial Intelligence (AI) is becoming increasingly prevalent in drug discovery and development and holds the potential to address the challenges in ADC development. AI requires substantial amounts of high-quality data to make reliable predictions of a novel ADC’s safety and efficacy. However, since this therapeutic area is still fairly new, there is limited data available to meet all the challenges of ADC development through AI. In such a scenario, enriching AI with knowledge (hybrid AI) is a very promising approach and provides high-accuracy predictions even in data-limited scenarios.

Following a series of successful initial preclinical proof of concept studies, Lonza's subsidiary Synaffix has licensed its antibody-drug conjugates (ADC-) technology to BigHat Biosciences. BigHat will combine...

Lantern Pharma has signed a research collaboration with Bielefeld University for the development of novel antibody-drug conjugates (ADCs) with high therapeutic and anti-tumor potential. The partners will be using Lantern's proprietary Response Algorithm for Drug Positioning and Rescue (RADR®) artificial intelligence (AI) and machine learning (ML) platform , to rapidly develop novel cryptophycin-antibody drug conjugates (ADCs), which represent an exciting class of potent and highly targeted drug candidates.

OSE Immunotherapeutics,  a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases and deep...